Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Effects of Antipsychotics in Children
NCT00205699Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2006
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in conduct disorder (CD), oppositional defiant disorder (ODD), Disruptive behavior disorders (DBD) and 5 more comparing Aripiprazole, Olanzapine and Risperidone (3 arms). Primary endpoints: Change in DEXA % Body Fat at 12 weeks and Change in Insulin-stimulated Glucose Rate of Disappearance at 12 weeks. Started Apr 2006; status: completed.
02
Drugs
olanzapinerisperidonearipiprazole
03
Conditions
conduct disorder (CD)oppositional defiant disorder (ODD)Disruptive behavior disorders (DBD)Autism Spectrum Disorder (ASD)pervasive developmental disorder (PDD)
Beyond the preview
Go deeper on NCT00205699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00205699.